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Abstract  
OBJECTIVE: To determine the immunopathological correlation between Cag A+ H. pylori-specific IgG; 
pepsinogen I&II (PI&PII); gastrin-17 (G-17); status of gastric and duodenal mucosa and inflammatory activities on 
different gastroduodenal disorders. 
METHODOLOGY: Eighty gastroduodenal biopsies were taken from patients with gastroduodenal disorders for 
histopathological evaluation and H. pylori diagnosis. Serum samples were used for evaluation of gastric hormones 
and detection of H. pylori-specific IgG antibodies. The tissue expression of H. pylori Cag A gene was detected by 
in situ hybridisation. 
RESULTS: H. pylori IgG antibodies were detected in (88.8%) of enrolled patients. According to Cag A gene 
expression, Significant difference (P value ˂ 0.05) was detected in levels of PG I; PGII, PG I/PG II among patients 
with gastric disorders. Serum G-17 level was negatively correlated with Cag A gene expression (P-value = 0.04). 
There was a significant correlation between H. pylori IgG and PG I; PG II; G-17. The current study revealed that 
corpus atrophic gastritis was diagnosed histologically with (5%) gastric ulcer cases; (3.75%) of duodenal ulcer 
cases; (3.75%) of duodenitis cases; (1.25%) of gastropathy cases and (8.75%) of gastritis cases. At the same 
time H. pylori gastritis diagnosed concurrently with (8.75%) of gastric ulcer cases; (11.25%) of duodenal ulcer 
cases; (17.5%) of gastropathy cases; (3.75%) of duodenitis cases and (2.5%) of prepyloric ulcer cases. A 
significant correlation was reported between the Immunopathological status of gastric mucosa and endoscopic 
mucosal finding among duodenal ulcer cases and gastritis cases only. A positive correlation was reported 
between serum levels of PGI; PGII; PGI/PGII; G-17; PMNs grade and Immunopathological status of the 
gastroduodenal mucosa of H. pylori Infected patients. A significant difference was reported in lymphocyte grades 
among gastric disorders without correlation with immunohistopathological changes in the mucosa (P-value = 
0.002). A significant difference was reported in lymphocyte grades among different disorders according to H. 
pylori IgG. A significant difference was reported in serum level of PG I; PG II; PG I/PG II; G-17 according to PMN 
and lymphocyte grades (P-value ˂ 0.01). PMNs grades positively correlated with gastric Cag A expression; H. 
pylori IgG; PG II; G-17 levels. PG I; PG I/ PG II correlated with lymphocyte grades (P-value ˂ 0.05); while PGII 
has a negative correlation (P-value = 0.039). 
CONCLUSION: Endoscopic mucosal finding does not reflect exactly the actual immunopathological changes of 
gastric mucosa during H. pylori infection. Secretion of gastrin was not affected by the presence of Cag A in gastric 
tissue. Instead, the fluctuation in the hormone level appears to be due to the presence of H. pylori infection in 
gastric tissue. Gastric tissue infiltration with PMNs & lymphocytes inflammatory infiltrates has a direct effect on 
PGs and gastrin levels in serum of infected patients. The level of PG I; PG II; G-17 secretion correlated with the 
development of immune response against H. pylori and production of specific H. pylori IgG. Finally, H. pylori can 
modulate gastric secretions through Cag A dependent and independent pathways. 
 
 
 
 
Introduction 
 
There are studies with evidence indicating 
that Helicobacter pylori play a role in the pathogenesis 
of various gastroduodenal disorders [1]. H. pylori 
colonisation of gastric tissue induces recruitment of 
inflammatory cells to the infected gastric epithelium 
and releasing of virulence factors from the bacteria as 
opposite reaction [2]. Gastritis induces disruption of 
acid secretion depending on the predominant location 
in the stomach, antrum or corpus [3] [4]. The 
gastroduodenal response to chronic H. pylori infection 
is characterised by infiltration of plasma cells, 
lymphocytes, neutrophils, and monocytes into gastric 
mucosa [2]. The gastric epithelium plays an active role 
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in the mucosal defence. Neutrophil activation and the 
production of reactive oxygen metabolites are induced 
directly by bacterial factors and indirectly via host-
derived cytokines and products of complement 
activation [5]. As well as stimulating specific T and B 
cell responses and systemic immunoglobulin (Ig) G 
and A antibody production, H. pylori infection also 
induces a local proinflammatory cytokine response 
and the development of gastric lymphoid follicles 
which are important in immune cells infiltration [3]. 
Pepsinogens (PG) are aspartic proteinases, 
which are mainly secreted by gastric cells. PG can be 
classified into two biochemically and immunologically 
distinct types: pepsinogen I (PGI) and pepsinogen II 
(PGII). PGI is secreted only from the gastric fundic 
mucosa by chief cells and mucous neck cells in the 
corpus area [6], while PGII is secreted from the 
cardiac, fundic, and antral mucosal epithelium of the 
stomach, and also from the duodenal mucosa [7]. 
Gastrin-17 is produced mainly by the G cells in the 
antrum. PGs are released into the circulation and 
serum PG level reflects the functional and 
morphologic status of the stomach mucosa. Gastrin-
17 (G-17) and pepsinogen I (PGI) levels respectively 
reflect distal and proximal stomach, while pepsinogen 
II (PGII) level, reflects the status of the entire stomach 
and particularly inflammation [8]. Human pepsinogens 
and gastrin have a diagnostic value for various 
gastroduodenal disorders, especially for peptic ulcer, 
atrophic gastritis and gastric cancer [9]. The 
pepsinogen I/II ratio can provide even better 
information on the extent of chronic gastritis [10]. 
The aim of present study was to detect in situ 
expression of H. pylori Cag A gene in gastroduodenal 
biopsies and determination of H. Pylori- specific IgG 
antibodies in serum samples taken from patients 
presented with gastroduodenal disorders. The second 
aim was the detection of serum level of gastric 
hormones (PGI, PGII, PG I/II ratio, G-17) among 
infected cases. Study the possible correlation 
between levels of PGI, PGII, PG I/II ratio, G-17, serum 
H Pylori-IgG antibodies; expression of Cag A gene in 
gastric tissue and status of gastroduodenal mucosa 
as well as the possible effects of H. pylori Cag A gene 
on levels of gastric hormones and mucosal 
inflammatory activity. 
 
 
Subjects and Methods 
 
This cross-sectional, hospital-based study 
was achieved at gastroenterology department of 
Baqubah teaching hospital in Diyala province-Iraq 
after approval of ethical review committee of 
Department of Pathology, College of Veterinary 
medicine-Diyala University-Iraq.  
A total of, 80 patients presented with clinical 
indications for upper gastrointestinal tract endoscopy 
during June 2013 to January 2015 were enrolled. The 
age range of attended patients (16-80 years) means 
(47.24 ± 18.82) years. Males represent 44 (55%) 
versus 36 (45%) females. 
This study was conducted according to the 
principles of Helsinki declaration. A full explanation of 
the purpose of this study to all patients was done 
before endoscopy. A signed duly filled consent form 
obtained from all patients that agree to participate in 
the study. Exclusion criteria were applied to any 
patient having a previous gastric surgery; recent or 
active gastrointestinal bleeding; under antibiotics or 
colloidal bismuth compounds for past one-month 
treatment. 
 
Methods 
A sterile flexible endoscope was introduced 
for a full investigation of stomach and duodenum after 
topical pharyngeal anaesthesia for overnight fasted 
Patients [4]. Any congested, inflamed or erosive 
lesions were picked via sterile biopsy forceps. 
Maximum 6 biopsies were taken. H. pylori urease 
activity was detected in biopsies by placing the 
samples in Serim® PyloriTek® Test Kit. Each 
PyloriTek® strip has a built-in positive analyte control 
and negative control, which run concurrently with the 
test specimen. The PyloriTek® positive control 
automatically appears with every test within the 
normal 1-hour time. With competitive tests, the 
positive control is run after waiting 24 hours then 
inserting a urease positive control material [11]. 
A sterile glass slide with a drop of normal 
saline was used to teasing the biopsy sample with a 
sterile scalpel to make smaller fragments of tissue 
then another sterile glass slide was placed over the 
teased first tissue, and the tissue was crushed 
between the two glasses then stain by Gram’s 
staining. The existence of Gram-negative spiral 
bacteria embedded in the tissue cells was diagnostic 
for H. pylori [12]. true positive results were considered 
if a combination of urease test and Gram stain give 
positive results for a single biopsy specimen [13]. 
In situ hybridisation procedure was used for 
detection of H. pylori Cag A gene expression in 5 µm 
thickness serial gastric mucosal sections fixed on 
positively charged slides using biotinylated long DNA 
probe for H.pylori/ Cag A Gene, Cat. No.: IH-
60061(HPY-6001-B) (Maxim biotech-USA) and the 
DNA Probe hybridisation/Detection System - In Situ 
Kit (Maxim biotech-USA), according to Maxim biotech 
instruction manual [14]. The examination and scoring 
were done under a light microscope by pathologists at 
powerX400 according to the scoring system [15].  
 The intensity of gastric inflammation was 
detected by recording lymphocyte infiltration in gastric 
tissue via grading scale from 0 to 3, based on both 
gastric lymphocyte and plasma cell infiltration. Grade 
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0 considered if normal cellular finding detected. Grade 
1 considered in case of low inflammation, Grade 2 for 
Moderate inflammation and Grade 3 indicate heavy 
inflammation [16]. Inflammation activity scored as 
following: None (Grade 0), Rare PMNs(Grade 1); 0-1 
intraepithelial (IE) PMN/hpf (Grade 2), Grade (3): 1-10 
intraepithelial (IE); PMN/hpf (Grade4): ≥10 IE 
PMN/hpf [5]. 
 For serological assay; blood was drawn from 
each patient during the visit to the endoscopy unit. 
Separated serum samples were stored at 27˚C until 
analyses. H pylori-specific IgG antibodies were 
determined using a monoclonal enzyme 
immunoassay method according to 
BIOHIT HealthCare instructions [17]. Serum 
pepsinogen I (PGI) and II (PGII) and gastrin-17 (G-17) 
were assayed with ELISA using monoclonal 
antibodies to PGI and II and G-17 (BIOHIT 
Diagnostics, Biohit, Devon, UK). All procedures were 
carried out according to the manufacturer’s 
instructions, and results of PGI and II reported in µg/l 
and pmol/l for gastrin-17. The pepsinogen I: II ratio 
was calculated and reported in fraction [17].  
The frequency of variables expressed as a 
percentage. PG I, II and G-17 values expressed as 
mean±standard deviation (Mean±SD). Pearson test 
for correlation was used for non-categorical data. Chi-
test used to compare the PG I, PGII, and G17 
according to CagA gene expression. The level of 
significance was 0.05 (two-tail) in all statistical tests. 
Significant of correlations(Pearson, Spearman) also 
include 0.01 (two-tail). Statistical analysis was 
performed using SPSS for Windows TM version 17.0, 
and Microsoft EXCEL for windows 2010.  
 
 
Results 
 
As shown in Table 1, the mean serum level 
for PGI (112.10 ± 87.73 µg/L) and (40.09 ± 50.80 
µg/L) for PGII. Hypersecretion of PGI (˃ 160µg/L) 
detected in (31.3%) of patients, mainly among 
gastropathy; gastritis (8.75%) and duodenal ulcer 
(DU), (7.5%).  
Table 1: Description of Gastric secretions and H. pylori-
specific serum IgG 
Parameters 
Minimu
m 
Maximu
m 
Mean±Std. 
Deviation 
Under 
normal Value 
Negative 
or normal 
value 
Positive or 
higher than 
normal 
Pepsinogen I 
(µg/L) 
4 400 112.10±87.73 
˂30 µg/L 
6 (7.5%) 
30-160 µg/L 
49 (61.3%) 
˃ 160 µg/L 
25 (31.3%) 
Pepsinogen II 
(µg/L) 
6 220 40.09± 50.80 
˂3 µg/L 
0 (0%) 
3-15 µg/L 
19 (23.8%) 
˃ 15 µg/L 
61 (76.3%) 
Pepsinogen I / 
Pepsinogen II 
ratio 
0.17 18.18 4.65± 4.13 
˂3 µg/L 
33 (41.3%) 
3-20 µg/L 
47 (58.8%) 
˃ 20 µg/L 
0 (0%) 
Gastrin 17 
(pmol/l) 
1 400 9.58± 44.30 
˂1 pmol/ml 
0 (0 %) 
1-7 pmol/ml 
70 (87.5%) 
˃ 7 pmol/ml 
10 (12.5%) 
H.pylori IgG (EIU) 
 
9.29 250 107.61±52.00 0 (0%) 
˂30-EIU 
9 (11.3%) 
˃30 EIU 
71 (88.8%) 
 
Normal secretion of PGI was detected in 
gastritis (28.75%) while hyposecretion detected in 
(3.77%) of gastric ulcer (GU) cases. A significant 
difference (P-value = 0.005) was detected among 
gastric disorders in PG I secretion levels as shown in 
(Table 2). 
Hypersecretion of PG II (˃ 15 µg/L) detected 
in (76.3%) patients mainly with gastritis (28.75%), 
gastropathy (16.25%) and DU (15%). The normal 
value of PG II was detected in (23.8%) of gastric 
disorders while hyposecretion of PGII not observed 
with significant difference (P value = 0.006). The 
mean of PG I/PG II ratio was 4.65 ± 4.13 µg/L. 
Hyposecretion of PG I/PG II detected in (41.3%), 
while hypersecretion of PGI/PG II not determined in all 
gastric disorders with significant difference (P value = 
0.000) (Table 2). 
The mean of G-17 (9.58 ± 44.30) (pmol/l). 
Normal range of G-17 (1-7pmol/l) detected in (87.5%) 
patients; Hypersecretion of G-17 detected in (12.5%) 
mainly among gastritis (7.5%) without significant 
difference (P value=0.49) among gastric disorders 
(Table 2). There was no correlation between serum 
levels of PG I; PG II; PG I/PG II or G-17 and type of 
gastroduodenal disorder as shown in Table 2.  
As shown in Table 3, the PG I hyposecretion 
(7.5%), normal (32.5%) and hypersecretion level 
(18.75%) was significantly higher in CagA positive (P-
value = 0.009) (Figure 1).  
 
Figure 1: In situ hybridisation for Cag A Positive H. pylori in a gastric 
tissue section, staining by BCIP/NBT (bluish purple) counterstained 
with nuclear fast red. Bar size = 50 µm; A) Gastric epithelia; B) Cag 
A expression extended to gastric pits; C) negative expression 
 
Significant difference was detected between 
CagA positive and CagA negative cases in PGII (P 
value = 0.005); PG I/PG II, (P value = 0.003). No 
significant difference was detected between patients 
in G-17 serum level; (P value=0.479). There was no 
correlation between CagA gene expression and 
serum levels of PG I; PGII; PG I/PGII but only for 
Gastrin17 (P value = 0.04). Significant difference and 
correlation between specific H. pylori IgG; PGI (P 
value = 0.000; P value = 0.004); PG II (P value = 
0.000; P value = 0.003); G-17 (P value = 0.000; P 
value = 0.05). Significant difference without correlation 
was detected between CagA positive and negative 
cases in PG I/PG II (P value = 0.000; P value = 0.215) 
as shown in Table 4. 
One of the most interesting points in the 
current study was that the endoscopic and 
microscopic examination of gastric mucosa revealed 
different findings as shown in Table 5.  
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Table 2: Correlation of Gastric Secretions with Gastroduodenal Disorders  
Parameter Gastric ulcer 
Duodenal 
ulcer 
Gastropathy Gastritis Duodenitis Prepyloric ulcer 
2 
P value 
r P value 
Pepsinogen I 
˂30 µg/L 4 (3.77%) 1 (1.25%) 0 (0%) 0 (0%) 1 (1.25%) 0 (0%) 
157.97 
0.005 
 
-0.016 
 
0.887 30-160 µg/L 8 (10%) 5 (6.25%) 8 (10%) 23 (28.75%) 5 (6.25%) 0 (0%) 
˃ 160 µg/L 3 (3.75%) 6 (7. 5%) 7 (8.75%) 7 (8.75%) 0 (0%) 2 (2.5%) 
Pepsinogen II 
˂3 µg/L 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
144.50 0.006 
-0.044 
 
0.698 3-15 µg/L 8 (10%) 0 (0%) 2 (2.5%) 7 (8.75%) 2 (2.5%) 0 (0%) 
˃ 15 µg/L 7 (8.75%) 12 (15%) 13 (16.25%) 23 (28.75%) 4 (3.77%) 2 (2.5%) 
Pepsinogen I/ 
Pepsinogen II ratio 
˂3 µg/L 2 (2.5%) 9 (11.25%) 3 (3.75%) 14 (17.5%) 5 (6.25%) 0 (0%) 
266.35 0.000 
- 0.054 
 
0.637 3-20 µg/L 13 (16.25%) 3 (3.75%) 12 (15%) 16 (20%) 1 (1.25%) 2 (1.89%) 
˃ 20 µg/L 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Gastrin17 
˂1 pmol/l 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
69.531 0.493 
0.075 
 
0.506 1-7 pmol/l 12 (15%) 12 (15%) 15 (18.75%) 24 (30%) 5 (6.25%) 2 (2.5%) 
˃ 7 pmol/l 3 (3.75%) 0 (0%) 0 (0%) 6 (7.5%) 1 (1.25%) 0 (0%) 
 
Gastric ulcer was diagnosed endoscopically in 
15 (18.75%) of patients; 4 (5%) of them have normal 
gastric mucosa and atrophic corpus gastritis equally, 
while 7 (8.75%) have H.pylori gastritis without atrophy. 
A total of 14 (17.5%) have inflamed mucosa during 
endoscopic examination. Among gastric ulcer cases, 
no significant correlation was reported between the 
Immunopathological status of gastric mucosa and 
endoscopic mucosal finding (P-value = 0.820). 
Table 3: Correlation of Gastric secretions with Cag A genotype 
and H. pylori-specific serum IgG 
Parameter 
CagA 
positive 
CagA 
Negative 
2 
 
P value r P value 
Pepsinogen I 
˂ 30 µg/L 6 (7. 5%) 0 (0%) 
41.900 0.009 0. 085 0.451 30-160µg/L 26 (32.5%) 23 (28.75%) 
>160 µg/L 15 18.75%) 10 (12.5%) 
Pepsinogen II 
˂3 µg/L 0 (0%) 0 (0%) 
41.55 0.005 0. 187 0.097 3-15 µg/L 11 13.75%) 8 (10%) 
>15 µg/L 36 (45%) 25 (31.25%) 
Pepsinogen I/ 
Pepsinogen II 
ratio 
˂ 3 µg/L 17 (21.25%) 16 (20%) 
64.52 0.003 0.003 0.980 3-20 µg/L 30 (37.5%) 17 (21.25%) 
>20 µg/L 0 (0%) 0 (0%) 
Gastrin 17 
˂ 1 pmol/l 0 (0%) 0 (0%) 
13.613 
 
0.479 
-0.147 
-0.229* 
0.194 
0.04* 
1-7 pmol/l 44 (55%) 26 (32.5%) 
>7 pmol/l 3 (3.75%) 7 (8.75%) 
 
The duodenal ulcer was diagnosed 
endoscopically in 12 (15%) of patients; 3 (3.75%) of 
them have atrophic corpus gastritis, while 9 (11.25%) 
have H. pylori gastritis without atrophy. Endoscopy 
mucosal finding revealed that a total of 9 (11.25%) 
have normal mucosa during endoscopic examination 
while 1 (1.25%) suffered from severe erosion and 2 
(2.5%) suffered from severe inflammation.  
Table 4: Correlation of Gastric secretions with H. pylori-
specific Serum IgG 
Parameter 
H. pylori 
IgG positive 
H. pylori 
IgG 
Negative 
2 P value r P value 
Pepsinogen I 
˂ 30 µg/L 3 (3.75%) 3 (3.75%) 
 
1352.800 
0.000 0.317 0.004 30-160 µg/L 44 (55%) 5 (6.25%) 
>160 µg/L 24 (30%) 1 (1.25%) 
Pepsinogen II 
˂3 µg/L 0 (0%) 0 (0%)  
1204.127 
 
 
0.000 
0.211 
0.328* 
0.06 
0.003* 
3-15 µg/L 11 (13.75%) 8 (10%) 
>15 µg/L 60 (75%) 1 (1.25%) 
Pepsinogen I/ 
Pepsinogen II 
ratio 
˂ 3 µg/L 32 (40%) 1 (1.25%) 
1914.333 
 
0.000 
0.140 
 
 
0.215 3-20 µg/L 39 (48.75%) 8 (10%) 
>20 µg/L 0 (0%) 0 (0%) 
Gastrin 17 
˂ 1 pmol/l 0 (0%) 0 (0%)  
593.539 
 
0.000 -0.220 
0.05 
 
1-7 pmol/l 65 (81.25%) 5 (6.25%) 
>7 pmol/l 6 (7. 5%) 4 (5%) 
* Spearman Correlation. 
 
Among duodenal ulcer cases, a significant 
difference (P value = 0.027) and the correlation were 
reported between the Immunopathological status of 
gastric mucosa and endoscopic mucosal finding (P-
value = 0.012) as shown in Table 5.  
Gastropathy was diagnosed endoscopically in 
15 (18.75%) of patients; 1 (1.25%) of them have 
atrophic corpus gastritis, while 14 (17.5%) have H. 
pylori gastritis without atrophy. Endoscopy mucosal 
finding revealed that all have inflamed mucosa during 
endoscopic examination. No statistics are computed 
because endoscopy mucosal finding is a constant as 
shown in Table 5. 
Gastritis was diagnosed endoscopically in 30 
(37%) of patients; 2 (2.5%) of patients have normal 
mucosa; 7 (8.75%) of them have atrophic corpus 
gastritis, while 21 (26.25%) have H. pylori gastritis 
without atrophy. Endoscopy mucosal finding revealed 
that a total of 1 (1.25%) have normal mucosa during 
endoscopic examination while 3 (3.75%) suffered from 
severe erosion and 26 (32.5%) suffered from severe 
inflammation.  
Among gastritis cases, a significant difference 
(P value = 0.001) and the correlation were reported 
between the Immunopathological status of gastric 
mucosa and endoscopic mucosal finding (P-value = 
0.004).  
Duodenitis was diagnosed endoscopically in 6 
(7.5%) of patients; 3 (3.75%) of them have atrophic 
corpus gastritis, while 3 (3.75%) have H. pylori 
gastritis without atrophy. Endoscopy mucosal finding 
revealed that a total of 2 (2.5%) during endoscopic 
examination suffered from severe erosion and 4 (5%) 
suffered from severe inflammation. Among duodenitis 
cases, no significant difference (P value = 0.083) nor 
correlation (P-value = 0.116) was reported between 
the Immunopathological status of gastric mucosa and 
endoscopic mucosal finding as shown in Table 5. 
Prepyloric Ulcer was diagnosed endoscopically in 2 
(2.5%) of patients; all have H. pylori gastritis without 
atrophy. Endoscopy mucosal finding revealed that 
patients suffered from severe inflammation.  
No statistics are computed because 
endoscopy mucosal finding is a constant. Status of 
gastroduodenal mucosa significantly differs and 
correlated with serum levels of PG I (P-value = 
0.0000); PG II (P-value = 0.029); PG I/PG II (P-value 
= 0.008); G-17 (P-value = 0.004) (Table 6). PMNs 
grades significantly correlated with (P-value = 0.02) 
status of gastroduodenal mucosa.  
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Table 5: Correlation of Clinical Diagnosis According To Endoscopy, Immunopathological Status of gastroduodenal mucosa and 
Endoscopic Mucosal Findings according to H. pylori infection 
Clinical Diagnosis According To 
Endoscopy 
Immuno-pathological Status of 
gastroduodenal mucosa 
Endoscopy Mucosal Finding 
Total 2 
P 
value 
r 
P 
value Normal 
Sever 
Erosion 
Inflammation 
Gastric Ulcer 
Normal Mucosa (No Infection) 0 (0%) 0 (0%) 4 (5%) 4 (5%) 
2.946 0.229 0.064 0.820 
Atrophic Corpus Gastritis 1 (1.25%) 0 (0%) 3 (3.75%) 4 (5%) 
H. pylori Gastritis Without Atrophy 0 (0%) 0 (0%) 7 (8.75%) 7 (8.75%) 
Total 1 (1.25%) 0 (0 %) 14 (17.5 %) 15 (18.75%) 
Duodenal ulcer 
Normal Mucosa (No Infection) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
7.259 .027 -0.697 0.012 
atrophic corpus gastritis 1 (1.25%) 0 (0%) 2 (2.5%) 3 (3.75%) 
H. pylori gastritis without atrophy 8 (10%) 1 (1.25%) 0 (0%) 9 (11.25%) 
Total 9 (11.25%) 1 (1.25%) 2 (2.5%) 12 (15%) 
Gastropathy 
Normal Mucosa (No Infection) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
ND ND* ND ND* 
atrophic corpus gastritis 0 (0%) 0 (0%) 1 (1.25%) 1 (1.25%) 
H. pylori gastritis without atrophy 0 (0%) 0 (0%) 14 (17.5%) 14 (17.5%) 
Total 0 (0%) 0 (0%) 0 (0%) 15 (18.75%) 
Gastritis 
Normal Mucosa (No Infection) 1 (1.25%) 0 (0%) 1 (1.25%) 2 (2.5%) 
17.866 .001 0.507 0.004 
atrophic corpus gastritis 0 (0%) 2 (2.5%) 5 (6.25%) 7 (8.75%) 
H. pylori gastritis without atrophy 0 (0%) 1 (1.25%) 20 (25%) 21 (26.25%) 
Total 1 (1.25%) 3 (3.75%) 26 (32.5%) 30 (37.5%) 
Duodenitis 
Normal Mucosa (No Infection) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
3.000 0.083 0.707 0.116 
atrophic corpus gastritis 0 (0%) 2 (2.5%) 1 (1.25%) 3 (3.75%) 
H. pylori gastritis without atrophy 0 (0%) 0 (0%) 3 (3.75%) 3 (3.75%) 
Total 0 (0%) 2 (2.5%) 4 (5%) 6 (7.5%) 
Prepyloric Ulcer 
Normal Mucosa (No Infection) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
ND ND* ND ND* 
atrophic corpus gastritis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
H. pylori gastritis without atrophy 0 (0%) 0 (0%) 2 (2.5%) 2 (2.5%) 
Total 0 (0%) 0 (0%) 2 (2.5%) 2 (2.5%) 
*No statistics are computed because endoscopy mucosal finding is a constant. ND: not detected. 
A significant difference (P-value = 0.002) in 
grades of mucosal lymphocyte infiltration among 
gastroduodenal disorders also, there was no 
correlation between grades of mucosal lymphocyte 
infiltration and histopathological changes in mucosa 
as shown in Table 7. 
As shown in Table 8, PMNs grades 
significantly correlated with Cag A expression (P value 
= 0.0000); H. pylori IgG (P value = 0.003). Significant 
difference in PG I (P value = 0.0000); PG II; PG I/PG 
II ratio; G-17 according to PMN grade. Significant 
correlation between PG II (P value = 0.009); G 17 (P 
value = 0.000) and PMNs Grade.  
As shown in Table 9, inflammation intensity 
according to lymphocyte grade do not correlate with 
Cag A expression and presence of H. pylori-specific 
IgG (P-value = 0.063), (P-value = 0.706). A significant 
difference in PG I (P-value = 0.0000); PG II; PG I/PG 
II ratio; G-17 according to lymphocyte grades; positive 
correlation between PG I (P-value = 0.007); PG I/PG II 
(P-value = 0.037) and lymphocyte grades. The 
negative correlation between PG II (P-value = 0.039) 
and lymphocyte grades. 
 
Discussion 
 
In this study, the age and gender distribution 
for H. pylori-infected patients come in line with [2] [5] 
[16] [18] and counteract with recent international 
studies [19]. H. pylori infection provokes both local 
and systemic antibody responses. The systemic 
response typically comprises a transient rise in IgM, 
followed by a rise in specific IgA and IgG maintained 
throughout infection [20].  
In this study, (88.8%) have H. pylori-specific 
IgG antibodies (˃ 30-EIU) which reflect the high level 
of immune response to H. pylori as the mean of H. 
pylori-specific IgG antibodies (107.61 ± 52) EIU, which 
come in agreement with [20] and higher than [21] [22], 
reporting H. pylori seropositivity of 56.3%; 57% of 
Indian and Saudi Arabia patients respectively. The 
negative H. pylori-specific IgG (˂ 30-EIU) was 
detected in (11.3%) but, histologically the infection 
proved through detection of Cag A gene expression in 
gastric tissue.  
Table 6: Correlation Of Gastric Secretions And Status Of Gastroduodenal Mucosa according to H. pylori Infection 
Parameter 
Immunopathological Status of gastroduodenal mucosa 
Total 
2 
 
P value 
Correlation 
H. pylori 
Associated atrophic 
corpus gastritis 
H. pylori 
Gastritis without 
atrophy 
Normal mucosa (no 
infection) 
r P value 
Pepsinogen I 
˂ 30 µg/L 6 (7.5%) 0 (0%) 0 (0%) 6 (7.5%) 
116.251 0.000 0.408 0.000 30-160 µg/L 12 (15%) 32 (40%) 5 (6.25%) 49 (61.25%) 
>160 µg/L 0 (0%) 24 (30%) 1 (1.25 %) 25 (31.25%) 
Pepsinogen II 
˂3 µg/L 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
94.710 0.000 0.244 0.029 3-15 µg/L 5 (6.25%) 9 (11.25%) 5 (6.25%) 19 (23.75%) 
>15 µg/L 13 (16.25%) 47 (58.75%) 1 (1.25 %) 61 (76.25%) 
Pepsinogen I/ Pepsinogen 
II ratio 
˂ 3 µg/L 15 (18.75%) 17 (21.25%) 1 (1.25 %) 33 (41.25%) 
148.229 0.000 
0.095 
0.294* 
0.403 
0.008* 
3-20 µg/L 3 (3.75%) 39 (48.75%) 5 (6.25%) 47 (58.75%) 
>20 µg/L 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Gastrin 17 
˂ 1 pmol/l 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
64.856 0.000 -0.317 0.004 1-7 pmol/l 17 (21.25%) 51 (63.75%) 2 (2.5%) 70 (87.5%) 
>7 pmol/l 1 (1.25%) 5 (6.25 %) 4 (5%) 10 (12.5%) 
* Spearman Correlation. 
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Table 7: Correlation of Inflammation intensity; activity and Immunopathological Status of gastroduodenal mucosa according to H. pylori Infection  
Pmns grade 
Status Of Gastroduodenal Mucosa According To H. pylori Infection 
Total 
2 
 
P value 
 
r 
P value Normal mucosa (No 
infection) 
H. pylori  corpus 
Gastritis with atrophy  
H. pylori gastritis 
Without atrophy 
0 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
6.625 0.157 0.260 0.02 
1 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
2 1 (1.25 %) 3 (3.75%) 2 (2.5%) 6 (7.5%) 
3 3 (3.75%) 9 (11.25%) 21 (26.25%) 33 (41.25%) 
4 2 (2.5%) 6 (7.5%) 33 (41.25%) 41 (51.25%) 
Total 6 (7.5%) 18 (22.5%) 56 (70%) 80 (100%) 
Lymphocyte grade  
Normal mucosa (No 
infection) 
Atrophic corpus 
gastritis 
H. pylori gastritis without 
atrophy 
Total 
2 
 
P value R 
 
P value 
0 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
17.475 0.002 0.037 0.746 
1 0 (0%) 2 (2.5%) 0 (0%) 2 (2.5%) 
2 0 (0%) 12 (15%) 24 (30%) 36 (45%) 
3 6 (7.5%) 4 (5%) 32 (40%) 42 (52.5%) 
Total 6 (7.5%) 18 (22.5%) 56 (70%) 80 (100%) 
 
It means recent infection with a scanty 
number of H.pylori and the time of infection less than 
20 IgG seroconversion occurs in 22-23 days after 
infection [21]. 
Fluctuations of H. pylori-specific IgG antibody 
titer predict the variation in response of the host 
against H. pylori. This may give a great possibility for 
continuous exposure of local population in Iraq to 
H. pylori because of low-quality drinking water, 
improper sanitation for household sewage, continuous 
exposure to H. pylori from other sources like raw 
vegetables. All these factors may act in development 
of the high level of humoral immune response in pre-
exposed persons [4]. 
One of motivating results in the current study 
was the hypersecretion of PGI (˃ 160 µg/L), in 
(31.3%) of patients while hyper secretion of PG II (˃ 
15 µg/L) in (76.3%), both of them among gastropathy; 
gastritis and duodenal ulcer (P value ˂ 0.05) indicating 
that the density of the pathogens distributed gradually 
to be pangastric and even duodenal region stimulating 
intracellular nitric oxide and calcium production 
inducing sever inflammatory response due to H. pylori 
that subsequently induce PGs hypersecretion [23] [24] 
Cag A expression in gastric tissue appears to 
play a role in hyposecretion of PGI by fundic gland 
that was detected in (7.5%) mainly in gastric and 
duodenal ulcers. All patients infected with Cag A
+
 H. 
pylori strain and have a positive association with anti-
H. Pylori IgG response and histologically gastric and 
duodenal ulcers associated with corpus atrophic 
gastritis (table 2, 3 and 4) which explain the main 
reason for hyposecretion of PGI. Hyposecretion of 
PGI/PGII detected in (41.3%) among them (21.25%) 
infected with Cag A
+
 H. pylori associated with (40%) 
anti-H. Pylori IgG response mainly among Duodenal 
ulcer, gastritis and duodenitis.  
Also, these cases associated with atrophic 
changes (Tables 2, 3 and 4), the main factor for such 
disturbance; besides heavy inflammation belongs to 
PGI because PGII which mainly secreted by pyloric 
glands and proximal duodenal mucosa still within 
normal range. These finding supported by others [25] 
[27] and come in agreement with [26] [28] [29], 
indicating that serum PG I/PG II ratio decreased when 
H. pylori infection occurs, but the ratio increased after 
eradication of the bacterium. 
In the current study, a normal range of G-17 
(1-7 pmol/l) was detected in (87.5%) of patients 
compared with (12.5%) associated with 
hypergastrinemia mainly among gastritis (7.5%). A 
significant correlation (P-value = 0.04) between Cag A 
expression and serum G-17 level was reported. A 
negative correlation was recorded between anti-H. 
pylori IgG and serum G17 which come in line with [3] 
[27]. The current study proved that no correlation 
between serum levels of PG I; PG II; PG I/PG II or G-
17 and type of gastroduodenal disorder that comes in 
line with [30]. 
 
Table 8: Correlation of gastric secretions; inflammatory activity according to PMNs grade; Cag A genotype; H. pylori-specific IgG 
Parameters 
Inflammatory activity  according to PMNs grade 
Total 2 P value r P  value 
0 1 2 3 4 
Cag A 
Genotype 
Negative 0 (0%) 0 (0%) 2 (2.5%) 24 (30%) 7 (8.75%) 33 (41.25%) 
23.536 0.000 0.381 0.000 
Positive 0 (0%) 0 (0%) 4 (5%) 9 (11.25%) 34 (42.5%) 47 (58.75%) 
H.pylori 
Igg 
˂30 EIU 0 (0%) 0 (0%) 4 (5%) 3 (3.75%) 2 (2.5%) 9 (11.25%) 
99.232 0.001 0.329 0.003 
˃30 EIU 0 (0%) 0 (0%) 2 (2.5%) 30 (37.5%) 39 (48.75%) 71 (88.75%) 
Pepsinogen I 
˂30 µg/L 0 (0%) 0 (0%) 3 (3.75%) 0 (0%) 3 (3.75%) 6 (7.5%) 
90.265 0.000 0.196 0.081 30-160 µg/L 0 (0%) 0 (0%) 3 (3.75%) 21 (26.25%) 25 (31.25%) 49 (61.25%) 
˃160 µg/L 0 (0%) 0 (0%) 0 (0%) 12 (15%) 13 (16.25%) 25 (31.25%) 
Pepsinogen II 
˂3 µg/L 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
92.322 0.000 0.290 0.009 3-15 µg/L 0 (0%) 0 (0%) 5 (6.25%) 6 (7.5%) 8 (10%) 19 (23.75%) 
˃15 µg/L 0 (0%) 0 (0%) 1 (1.25%) 27 (33.75%) 33 (41.25%) 61 (76.25%) 
Pepsinogen I / 
Pepsinogen II 
˂3 µg/L 0 (0%) 0 (0%) 0 (0%) 15 (18.75%) 18 (22.5%) 33 (41.25%) 
131.843 0.000 -0.64 0.573 3-20 µg/L 0 (0%) 0 (0%) 0 (0%) 18 (22.5%) 23 (28.75%) 47 (58.75%) 
˃20 µg/L 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Gastrin 17 
˂1 pmol/l 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
40.236 0.05 
-0.107 
-0.426* 
0.347 
0.000* 
1-7 pmol/l 0 (0%) 0 (0%) 4 (5%) 25 (31.25%) 41 (51.25%) 70 (87.5%) 
˃7 pmol/l 0 (0%) 0 (0%) 2 (2.5%) 8 (10%) 0 (0%) 10 (30%) 
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Table 9: Correlation of gastric secretions; inflammatory intensity according to lymphocytes grade; Cag A genotype; H. pylori-specific IgG 
Parameters 
Lymphocyte grade 
Total 2 P value r P value 
0 1 2 3 
Cag A In situ 
Negative 0 (0%) 2 (2.5%) 17 (21.25%) 14 (17.5%) 33 (41.25%) 
4.465 0.107 0.209 0.063 
Positive 0 (0%) 0 (0%) 19 (23.75%) 28 (35%) 47 (58.75%) 
H. Pylori 
Antibodies 
˂30 EIU 0 (0%) 0 (0%) 3 (3.75%) 6 (7.5%) 9 (11.25%) 
83.222 0.017 -0.043 0.706 
˃30 EIU 0 (0%) 2 (2.5%) 33 (41.25%) 36 (45%) 71 (88.75%) 
Pepsinogen I 
˂30 µg/L 0 (0%) 0 (0%) 6 (7.5%) 0 (0%) 6 (7.5%) 
90.860 0.000 0.302 0.007 30-160 µg/L 0 (0%) 2 (2.5%) 23 (28.75%) 24 (30%) 49 (61.25%) 
˃160 µg/L 0 (0%) 0 (0%) 7 (8.75%) 18 (22.5%) 25 (31.25%) 
Pepsinogen II 
 
 
˃3 µg/L 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
64.346 0.015 -0.232 0.039 3-15 µg/L 0 (0%) 0 (0%) 8 (10%) 11 (13.75%) 19 (23.75%) 
˃15 µg/L 0 (0%) 0 (0%) 2 (2.5%) 28 (35%) 31 (38.75%) 
Pepsinogen I/ 
Pepsinogen II 
˂3 µg/L 0 (0%) 2 (2.5%) 24 (30%) 7 (8.75%) 33 (41.25%) 
154.153 0.000 0.233 0.037 3-20 µg/L 0 (0%) 0 (0%) 12 (15%) 35 (43.75%) 47 (58.75%) 
˃20 µg/L 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Gastrin 17 
˂ 1 pmol/l 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
50.834 0.005 0.107 0.346 1-7 pmol/l 0 (0%) 2 (2.5%) 33 (41.25%) 35 (43.75%) 70 (87.5%) 
˃7 pmol/l 0 (0%) 0 (0%) 3 (3.75%) 7 (8.75%) 10 (12.5%) 
 
The interaction between H. pylori and gastrin 
was shown to be specific, essential and depends on a 
defined gastrin sequence. In the current study, H. 
pylori cause hypergastrinemia in (12.5%) of infected 
patients. Enhancement of gastrin secretion in the 
majority of H. pylori-infected patients might be due to 
several factors. First, increase in leptin production that 
may be induced after meal or H. pylori infection due to 
direct effect of cholecystokinin (CCK) secretion [30]; 
reduction of somatostatin secretion as a results of H. 
pylori infection [31] which leads to disruption of the 
inhibitory effect of somatostatin on the G cell [32]. 
Mucosal cytokines as a result of H. pylori infection, 
mainly TNFα and IL1β increase gastrin production via 
G cells [33]. Increased gastrin level reflect the activity 
of H. pylori CagA positive strains in the induction of G 
cells to increase gastrin mRNA expression in gastric 
mucosa [31] which give support for present findings 
that all gastric hormones significantly affected by 
CagA production in situ [27] [34]. 
One of the most interesting points in the 
current study that the endoscopic examination of H. 
pylori-infected gastric mucosa comes with different 
findings when further assessments take place via 
histopathology and serological evaluation of GI, GII, 
G17 (Table 4). This fact reflects the needs for further 
evaluation of endoscopically H. pylori positive cases 
via histopathological and serological gastric 
biomarkers for identification of numerous lesions that 
occurs concurrently in a single patient.  
One of the most valuable points in the present 
study, which revealed by the endoscopic and 
microscopic examinations of gastric mucosa was 
different findings. The endoscopic results not exactly 
reflect the immunopathological changes in gastric 
tissue. The current study revealed that corpus 
atrophic gastritis was diagnosed histologically in (5%) 
gastric ulcer cases; (3.75%) of duodenal ulcer cases; 
(3.75%) of duodenitis cases; (1.25%) of gastropathy 
cases and (8.75%) of gastritis cases. 
At the same time H. pylori gastritis diagnosed 
concurrently with (8.75%) of gastric ulcer cases; 
(11.25%) of duodenal ulcer cases; (17.5%) of 
gastropathy cases; (3.75%) of duodenitis cases and 
(2.5%) of prepyloric ulcer cases. A significant 
correlation was reported between the 
Immunopathological status of gastric mucosa and 
endoscopic mucosal finding among gastritis cases in 
which only (1.25%) has normal mucosa and (3.75%) 
have severe erosion while (32.5%) suffered from 
severe inflammation. Among duodenal ulcer cases 
(11.25%) have normal mucosa during endoscopic 
examination while (1.25%) suffered from severe 
erosion and (2.5%) suffered from severe 
inflammation. 
These results come in line with [1] [35] and 
give assumption of the heavy intensity of Cag A 
positive (58.75%) H. pylori colonization leads to 
severe inflammatory response and finally to reduction 
of PGI; PGI/PGII ratio and level of gastrin-17 
increased significantly in subjects with atrophic 
gastritis, which affect the morphology and function of 
gastric mucosa [3].  
A significant correlation was detected 
between gastric secretions (PGI and PGII; G-17) and 
status of the gastroduodenal mucosa, whether 
normal, atrophic or inflamed. Hyposecretion of PGI 
was reported in (7.5%) of H. pylori-associated atrophic 
corpus gastritis cases, due to the loss of mucosal 
glands and cells which come in line with [3] [36]. 
Reasonable hypersecretion of PGI (> 160 µg/L ) was 
detected in (30%) of cases with H. pylori mucosal 
gastritis which may be progressed to ulcers due to 
hyperchlorhydria [7]. Hypersecretion of PGII was 
detected in (58.75%) of H. pylori mucosal gastritis 
which gives an obvious indication of pangastric 
inflammatory pattern compared with (16.25%) in H. 
pylori-associated atrophic corpus gastritis, that may 
indicate a starting of damage to PGII producing chief 
cells, which come in accordance with other studies [8]. 
Hypergastrinemia detected among (6.25%) of H. 
pylori-associated gastritis without atrophy and in (5%) 
of normal mucosa which explains the role of H. pylori 
infection in limitation of inhibitory activity of D cells 
producing somatostatin against gastrin production via 
G cells which come by others [3] [31]. 
In the current study, a significant correlation 
(P-value = 0.02) between the status of gastroduodenal 
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mucosa whether associated with atrophic changes or 
not and grade of PMNs infiltrated in lamina propria 
associated with H. pylori Infection. No correlation 
between grades of mucosal lymphocyte infiltration and 
histopathological changes in mucosa was reported. 
These results come in line with others, stated that 
gastric inflammation with H. pylori has a considerable 
impact on the gastric morphology and acid secretion 
[3]. The present study finding has support from 
previous studies stated a significant correlation 
between atrophic changes in the gastric mucosa of 
Iraqi patients and the activity of lymphocytes and 
PMNs infiltrated [16]. 
Reasonable significant correlation between 
PMNs grades infiltration; specific H. pylori IgG and 
Cag A genotype in situ expression among different 
disorders were reported, which come by others [5] 
[16] [25]. The present study reported no correlation 
(P-value = 0.063) between Cag A in situ expressions; 
lymphocyte grades infiltration and specific H. pylori 
IgG among different disorders. This may attribute to 
the fact that numerous virulence factors associated 
with induction of inflammatory response in infected 
patients like iceA1, vac A and oip A [37]. 
A significant difference (P-value = 0.0000) 
was detected in serum level of PG I; PG II; PG I/PG II 
ratio; G-17 according to PMNs grade and lymphocyte 
grades. Significant correlation was detected between 
PG II (P-value = 0.009); G-17 (P-value = 0.000)and 
PMNs Grade, which come in agreement with [6] [38], 
they proved that serum levels of PG II and G 17 
increased when gastric mucosa is infiltrated with 
neutrophils and mononuclear cells in antrum as a 
result of H. pylori infection and its extension into the 
upper stomach. Others stated that gastrin levels were 
related to H. pylori density and acute/chronic 
inflammation scores in the corpus mucosa but not in 
the antral mucosa [39]. 
The present study recorded a positive 
correlation between PG I; PG I/PG II ratio and 
lymphocyte grades infiltrated in lamina propria. While 
negative correlation was detected between PG II and 
lymphocyte grades. This finding was supported by 
previous studies which recorded a correlation 
between H. pylori infection, inflammatory activity in-
situ and gastric hormones fluctuation before and after 
eradication, suggesting that the H. pylori-induced 
heavy inflammation is a strong stimulus for the 
synthesis of these biomarkers [6] [40].  
In conclusion, the endoscopic mucosal finding 
does not reflect exactly the actual immunopathological 
changes of gastric mucosa during H. pylori infection. 
Secretion of gastrin was not affected by the presence 
of Cag A in gastric tissue. Instead, the fluctuation in 
the hormone level appears to be due to the presence 
of H.pylori infection in gastric tissue. Infiltration of 
gastric tissue with inflammatory infiltrates mainly 
PMNs and lymphocytes has a direct effect on PGI; 
PGII and gastrin levels in serum of infected patients. 
The level of PG I; PG II; G-17 secretion correlated 
with the development of immune response against H. 
pylori and production of specific H. pylori IgG. Finally, 
H. pylori have the ability to modulates gastric 
secretions through CagA dependent and independent 
pathways. 
Current results recommend the need for 
further Intensive studies to determine the network of 
other virulence factors that play a destructive role on 
the level of gastric hormones and lead to tissue 
damage that may alter the clinical pathway from 
simple inflammation to the tumour. 
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